Biologicals

Meningococcal

Recommendations to assure the quality, safety and efficacy of Group A Meningococcal Conjugate vaccines

ECBS 2006

Recommendations for the production and control of group C meningococcal conjugate vaccines, TRS 926, Annex 3

Recommendations for the production and control of Meningococcal group C conjugate vaccines, TRS 924, 2004, Annex 2

Requirements for Meningococcal Polysaccharide vaccine (Amendment 1999) TRS 904, 2002 Annex 2

Requirements for meningococcal polysaccharide vaccine, Addendum 1980, TRS 658 Annex 6

Requirements for Meningococcal Polysaccharide vaccine: Adopted 1975, TRS 594, Annex 2

ESSENTIAL MEDICINES AND HEALTH PRODUCTS



UPCOMING EVENTS


  • WHO working group meeting on RSV vaccine standardization and clinical evaluation, Geneva, Switzerland, 3-5 February 2016
  • TCV Workshop, NIBSC, Potters Bar, UK, 8-10 March 2016
  • WHO informal consultation on labelling information on influenza vaccines intended to be used for pregnant women, Geneva, Switzerland, 4-5 April 2016
  • WHO informal consultation on WHO guidelines on regulatory preparedness for vaccine non-producing countries in response to pandemic influenza emergency, Geneva, Switzerland, 6-7 April 2016
  • WHO working group meeting on guidelines on the quality, safety and efficacy of Ebola vaccines, Geneva, Switzerland, 4-5 May 2016

Contacts


Technologies Standards and Norms (TSN)
Essential Medicines and Health Products (EMP)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971